Quest Partners LLC raised its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 2,826.7% during the second quarter, HoldingsChannel.com reports. The fund owned 439 shares of the company’s stock after purchasing an additional 424 shares during the period. Quest Partners LLC’s holdings in Prestige Consumer Healthcare were worth $30,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of PBH. Principal Securities Inc. acquired a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth $29,000. Vanguard Personalized Indexing Management LLC bought a new position in Prestige Consumer Healthcare in the fourth quarter valued at about $222,000. Quadrant Capital Group LLC boosted its stake in shares of Prestige Consumer Healthcare by 29.3% during the fourth quarter. Quadrant Capital Group LLC now owns 1,660 shares of the company’s stock valued at $102,000 after purchasing an additional 376 shares in the last quarter. Norges Bank bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth about $27,739,000. Finally, UBS Group AG increased its stake in shares of Prestige Consumer Healthcare by 377.6% in the fourth quarter. UBS Group AG now owns 131,382 shares of the company’s stock valued at $8,043,000 after buying an additional 103,872 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.
Prestige Consumer Healthcare Trading Down 1.2 %
NYSE:PBH opened at $73.01 on Friday. Prestige Consumer Healthcare Inc. has a 52 week low of $56.34 and a 52 week high of $75.80. The firm’s fifty day moving average is $71.22 and its 200-day moving average is $69.67. The firm has a market cap of $3.62 billion, a P/E ratio of 17.51, a P/E/G ratio of 2.08 and a beta of 0.48. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.90 and a current ratio of 3.23.
Wall Street Analysts Forecast Growth
Separately, DA Davidson boosted their target price on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $98.75.
View Our Latest Stock Report on PBH
Prestige Consumer Healthcare Profile
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Read More
- Five stocks we like better than Prestige Consumer Healthcare
- How to Invest in Blue Chip Stocks
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report).
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.